MIRM - Mirum draws $60 target from Morgan Stanley on liver disease prospects
2023-11-13 14:38:40 ET
More on Mirum
- Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
- Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
- Mirum Pharmaceuticals Q3 2023 Earnings Preview
- Cantor starts Mirum at overweight, sees peak sales of over $1B
- Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals
For further details see:
Mirum draws $60 target from Morgan Stanley on liver disease prospects